OMERS Administration Corp
KYTX icon

OMERS Administration Corp’s Kyverna Therapeutics KYTX Stock Holding History

OMERS Administration Corp’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,800
Closed -$128K – 1158
2026
Q1 		$128K Sell
14,800
-20,000
-57% -$167K ﹤0.01% 982
2025
Q4 		$327K Buy
+34,800
New +$258K ﹤0.01% 787

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

OMERS Administration Corp's KYTX Position: Q2 2026 in Review

OMERS Administration Corp sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 14,800 shares — an estimated $128K sold.

OMERS Administration Corp first reported a position in KYTX in Q4 2025 and held it in 2 quarters. The position peaked at $327K in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • OMERS Administration Corp reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 14,800 Kyverna Therapeutics shares in Q2 2026, an estimated $128K.
  • OMERS Administration Corp first reported a position in Kyverna Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Kyverna Therapeutics position peaked at $327K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.